Antibiotic drug discovery: new targets and molecular entities
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Royal Society of Chemistry
[2017]
|
| Schriftenreihe: | RSC drug discovery series
58 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | xv, 271 Seiten Illustrationen, Diagramme |
| ISBN: | 9781782624240 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV044867945 | ||
| 003 | DE-604 | ||
| 005 | 20180329 | ||
| 007 | t | ||
| 008 | 180315s2017 a||| |||| 00||| eng d | ||
| 020 | |a 9781782624240 |c hbk. : £169.00 |9 978-1-78262-424-0 | ||
| 020 | |z 9781782629870 |c : £169.00 |9 978-1-78262-987-0 | ||
| 020 | |z 9781788011495 |c : £169.00 |9 978-1-78801-149-5 | ||
| 035 | |a (OCoLC)1000314469 | ||
| 035 | |a (DE-599)BSZ488950856 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 084 | |a VS 8700 |0 (DE-625)147719:253 |2 rvk | ||
| 245 | 1 | 0 | |a Antibiotic drug discovery |b new targets and molecular entities |c edited by Steven M. Firestine (Wayne State University, Detroit, USA) and Troy Lister (Spero Therapeutics, Cambridge, USA) |
| 264 | 1 | |a Cambridge |b Royal Society of Chemistry |c [2017] | |
| 300 | |a xv, 271 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a RSC drug discovery series |v 58 | |
| 650 | 0 | 7 | |a Antibiotikum |0 (DE-588)4002257-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Antibiotikum |0 (DE-588)4002257-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Firestine, Steven M. |0 (DE-588)1137188782 |4 edt | |
| 700 | 1 | |a Lister, Troy |0 (DE-588)1137189061 |4 edt | |
| 830 | 0 | |a RSC drug discovery series |v 58 |w (DE-604)BV036776227 |9 58 | |
| 856 | 4 | 2 | |m HEBIS Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030262448&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030262448 | ||
Datensatz im Suchindex
| _version_ | 1804178396527198208 |
|---|---|
| adam_text | Contents
Chapter 1 Treatment of Clostridium difficile Infections 1
Christopher Yip, Jacqueline Phan and Ernesto Abel-Santos
1 1 Background 1
1 2 CDI Symptoms and Progression 5
1 3 Relapse 5
1 4 Diagnosis 6
1 5 Prevention Measures—General Hospital Practice
and Other Prevention Methods 7
1 6 Current Treatment and Antibiotics 9
161 Anti-Toxins 10
162 Vaccines 12
163 Anti-Germinants 13
164 Fecal Transplantation 13
165 Probiotics 14
1 7 Conclusion 15
References 15
Chapter 2 Targeting Purine Biosynthesis for Antibacterial
Drug Design 20
Gyan Modi, Shibin Chacko and Lizbeth Hedstrom
2 1 Introduction 20
211 The De novo Purine Nucleotide Biosynthesis
Pathway 21
212 The Purine Conversion Pathways 22
213 The Purine Salvage Pathways 24
214 Availability of Purine Bases and Nucleosides 25
Drug Discovery Series No 58
Antibiotic Drug Discovery: New Targets and Molecular Entities
Edited by Steven M Firestine and Troy Lister
© The Royal Society of Chemistry 2017
Published by the Royal Society of Chemistry, www rsc org
xi
Contents
215 The Complex Interplay Between Salvage
Pathways and Precursor Availability
2 2 The Essentiality of Enzymes of the Purine
Biosynthetic Pathways
221 Essentiality of Purine Nucleotide Biosynthesis
for Growth in Rich Media
222 Essentiality of Purine Nucleotide Biosynthesis
During Infection
223 Inhibitors May Not Have the Same
Phenotypes as Gene Knockouts
224 The Problem of Resistance
2 3 Progress Targeting the Enzymes of De novo Purine
Nucleotide Biosynthesis
2 4 Progress Targeting Enzymes in the Purine Nucleotide
Conversion Pathways
241 IMPDH Structure and Mechanism
242 Prokaryotic and Eukaryotic IMPDHs: A
Comparative Analysis of Rational Drug Design
243 Repurposing Cryptosporidium IMPDH
Inhibitors as Antibiotics
2 5 Conclusion
Acknowledgements
References
Chapter 3 Inhibitors of Biofilm Production
Roberta J Melander and Christian Melander
3 1 Introduction
3 2 Biofilms
3 3 Strategies for Combating Biofilms
331 Quorum Sensing Inhibitors
332 Inhibitors of AHL Based Quorum Sensing as
Biofilm Inhibitors
333 Inhibitors of AIP-Based Quorum Sensing as
Biofilm Inhibitors
334 Inhibitors of AI-2 Based Quorum Sensing as
Biofilm Inhibitors
3 4 Inhibition of Bacterial Signaling Pathways
341 Interference with c-di-GMP Signaling to
Inhibit Biofilm Formation
342 Inhibition of Indole Signaling Pathways to
Prevent Biofilm Formation
343 Inhibition of Two-Component Signal
Transduction Systems (TCS) to Prevent
Biofilm Formation
344 Inhibition of Other Signaling Pathways to
Prevent Biofilm Formation
25
26
26
27
30
30
30
31
32
34
36
38
38
39
43
43
43
44
44
45
47
48
49
49
50
52
53
Contents
xiii
3 5 Identification of Natural Products and Analogues
that Prevent Biofilm Formation 54
351 Plant Natural Products and Analogues that
Prevent Biofilm Formation 54
352 Marine Natural Products and Analogues that
Prevent Biofilm Formation 55
353 Other Natural Products that Prevent Biofilm
Formation 58
3 6 Antimicrobial Peptides (AMPs) that Prevent Biofilm
Formation 58
3 7 Inhibition of Efflux to Prevent Biofilm Formation 60
3 8 Matrix Degradation to Prevent Biofilm Formation 60
3 9 Conclusions 62
References 62
Chapter 4 Narrow Spectrum Antibacterial Agents 76
Lauren A Spagnuolo, Peter J Tonge and Stewart L Fisher
4 1 Introduction 76
4 2 Natural Products 80
4 3 Synthetic and Target-Based Approaches 86
4 4 Future Prospects 93
4 5 Conclusions 95
References 95
Chapter 5 The LPS Transport Pathway: A New Target for the
Development of Gram-Negative Antibiotics 103
Alison M Berezuk and CezarM Khursigara
5 1 Introduction 103
5 2 Lipopolysaccharide (LPS) and the
Gram-Negative Cell Envelope 105
5 3 The LPS Biosynthesis Pathway 106
531 Kdo2-Lipid A 106
532 Core Polysaccharide 109
533 O-Antigen 111
5 4 LPS Modification and Its Role in Gram-Negative
Bacterial Persistence 111
5 5 LPS Transport: The Lpt Pathway 112
551 Extraction of LPS from the IM 112
552 Traversing the Periplasm: The LptA Protein
Bridge 113
553 LPS Insertion into the OM 114
5 6 LPS Transport as a New Target for the
Development of Gram-Negative Antibiotics 115
5 7 Conclusions 120
References 120
XIV
Contents
Chapter 6 The Discovery of Teixobactin 127
L Lazarides, JYC Chiva, M Jones and V A Steadman
6 1 Introduction 127
6 2 Cultivating the Unculturable - The iChip 128
6 3 Teixobactin - A Novel Antibiotic 129
6 4 Structural Determination of Teixobactin 130
6 5 Synthesis of Teixobactin and Analogues 135
6 6 Conclusion 139
References 139
Chapter 7 Emerging Targets in Anti-Tubercular Drug Design 141
Keith D Green, Selina Y L Holbrook, Huy X Ngo
and Sylvie Garneau-Tsodikova
7 1 Introduction 141
711 The Biology and Pathology of TB 145
712 Current Drug Targets 148
713 Resistance Related to TB 150
7 2 Discovery and Validation of Novel Drug
Targets in TB 153
721 Targets Involved in Mycobacterium
tuberculosis Cell Envelope Biosynthesis 153
722 Targets Involved in Mycobacterium
tuberculosis General Metabolism 164
7 3 Synergistic Drug Combination Therapy 186
731 Unrelated Compounds 186
732 Inhibitors of Resistance Enzymes 186
733 P2X7 Receptor Agonist 187
7 4 Conclusion and Perspectives 188
Acknowledgements 188
References 188
Chapter 8 Antibacterial Leads Targeting Isoprenoid Biosynthesis 204
Carl J Balibar
8 1 Introduction 204
8 2 Targeting the MVA Pathway 207
821 Historic Compounds Inhibiting the MVA
Pathway 207
822 Screening for Inhibitors of the MVA
Pathway in Bacteria 208
823 Targeting the GHMP Kinase Family
Members of the MVA Pathway 209
8 3 Targeting the MEP Pathway 211
831 Historic Compounds Inhibiting the
MEP Pathway 211
Contents
xv
832 Inhibiting DXS 213
833 Inhibiting IspC 217
834 Inhibiting IspD 226
835 Inhibiting IspE 227
836 Inhibiting IspF 231
837 Inhibiting IspG and IspH 234
8 4 Alternate Targets Utilizing IPP Precursors 236
841 Inhibiting IDI 236
842 Inhibiting UppS 238
843 Inhibiting Staphyloxanthin Biosynthesis 243
8 5 Conclusions 245
References 246
|
| any_adam_object | 1 |
| author2 | Firestine, Steven M. Lister, Troy |
| author2_role | edt edt |
| author2_variant | s m f sm smf t l tl |
| author_GND | (DE-588)1137188782 (DE-588)1137189061 |
| author_facet | Firestine, Steven M. Lister, Troy |
| building | Verbundindex |
| bvnumber | BV044867945 |
| classification_rvk | VS 8700 |
| ctrlnum | (OCoLC)1000314469 (DE-599)BSZ488950856 |
| discipline | Chemie / Pharmazie |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01630nam a2200373 cb4500</leader><controlfield tag="001">BV044867945</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180329 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">180315s2017 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781782624240</subfield><subfield code="c">hbk. : £169.00</subfield><subfield code="9">978-1-78262-424-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781782629870</subfield><subfield code="c">: £169.00</subfield><subfield code="9">978-1-78262-987-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781788011495</subfield><subfield code="c">: £169.00</subfield><subfield code="9">978-1-78801-149-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1000314469</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ488950856</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 8700</subfield><subfield code="0">(DE-625)147719:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antibiotic drug discovery</subfield><subfield code="b">new targets and molecular entities</subfield><subfield code="c">edited by Steven M. Firestine (Wayne State University, Detroit, USA) and Troy Lister (Spero Therapeutics, Cambridge, USA)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Royal Society of Chemistry</subfield><subfield code="c">[2017]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xv, 271 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">RSC drug discovery series</subfield><subfield code="v">58</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antibiotikum</subfield><subfield code="0">(DE-588)4002257-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antibiotikum</subfield><subfield code="0">(DE-588)4002257-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Firestine, Steven M.</subfield><subfield code="0">(DE-588)1137188782</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lister, Troy</subfield><subfield code="0">(DE-588)1137189061</subfield><subfield code="4">edt</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">RSC drug discovery series</subfield><subfield code="v">58</subfield><subfield code="w">(DE-604)BV036776227</subfield><subfield code="9">58</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HEBIS Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030262448&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030262448</subfield></datafield></record></collection> |
| id | DE-604.BV044867945 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:03:18Z |
| institution | BVB |
| isbn | 9781782624240 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030262448 |
| oclc_num | 1000314469 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | xv, 271 Seiten Illustrationen, Diagramme |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | Royal Society of Chemistry |
| record_format | marc |
| series | RSC drug discovery series |
| series2 | RSC drug discovery series |
| spelling | Antibiotic drug discovery new targets and molecular entities edited by Steven M. Firestine (Wayne State University, Detroit, USA) and Troy Lister (Spero Therapeutics, Cambridge, USA) Cambridge Royal Society of Chemistry [2017] xv, 271 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier RSC drug discovery series 58 Antibiotikum (DE-588)4002257-2 gnd rswk-swf Antibiotikum (DE-588)4002257-2 s DE-604 Firestine, Steven M. (DE-588)1137188782 edt Lister, Troy (DE-588)1137189061 edt RSC drug discovery series 58 (DE-604)BV036776227 58 HEBIS Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030262448&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Antibiotic drug discovery new targets and molecular entities RSC drug discovery series Antibiotikum (DE-588)4002257-2 gnd |
| subject_GND | (DE-588)4002257-2 |
| title | Antibiotic drug discovery new targets and molecular entities |
| title_auth | Antibiotic drug discovery new targets and molecular entities |
| title_exact_search | Antibiotic drug discovery new targets and molecular entities |
| title_full | Antibiotic drug discovery new targets and molecular entities edited by Steven M. Firestine (Wayne State University, Detroit, USA) and Troy Lister (Spero Therapeutics, Cambridge, USA) |
| title_fullStr | Antibiotic drug discovery new targets and molecular entities edited by Steven M. Firestine (Wayne State University, Detroit, USA) and Troy Lister (Spero Therapeutics, Cambridge, USA) |
| title_full_unstemmed | Antibiotic drug discovery new targets and molecular entities edited by Steven M. Firestine (Wayne State University, Detroit, USA) and Troy Lister (Spero Therapeutics, Cambridge, USA) |
| title_short | Antibiotic drug discovery |
| title_sort | antibiotic drug discovery new targets and molecular entities |
| title_sub | new targets and molecular entities |
| topic | Antibiotikum (DE-588)4002257-2 gnd |
| topic_facet | Antibiotikum |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030262448&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV036776227 |
| work_keys_str_mv | AT firestinestevenm antibioticdrugdiscoverynewtargetsandmolecularentities AT listertroy antibioticdrugdiscoverynewtargetsandmolecularentities |